Τίτλος:
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: Final analysis of a phase 2 study
Συγγραφείς:
Kastritis, E.
Gavriatopoulou, M.
Kyrtsonis, M.-C.
Roussou, M.
Hadjiharissi, E.
Symeonidis, A.
Repoussis, P.
Michalis, E.
Delimpasi, S.
Tsatalas, K.
Tsirigotis, P.
Vassou, A.
Vervessou, E.
Katodritou, E.
Gika, D.
Terpos, E.
Dimopoulos, M.A.
Λέξεις-κλειδιά:
cyclophosphamide; dexamethasone; rituximab; antineoplastic agent; cyclophosphamide; dexamethasone; rituximab, adult; aged; cancer patient; disease course; human; intention to treat analysis; Letter; multiple cycle treatment; phase 2 clinical trial (topic); priority journal; progression free survival; remission; treatment outcome; treatment response; Waldenstroem macroglobulinemia; clinical trial; controlled study; disease free survival; middle aged; multicenter study; phase 2 clinical trial; randomized controlled trial; very elderly; Waldenstrom Macroglobulinemia, Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Disease-Free Survival; Humans; Middle Aged; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia
